Acute lymphoblast leukemia
Conditions
Interventions
Experimental group:Chimeric antigen receptor T cells
Sponsors
Department of Hematology, Xinqiao Hospital, Third Military Medical University, China
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Male or Femal with any ages; 2. The patients with the B-cell acute lymphoblast leukemia with molecular relapse after allogeneic hematopoietic stem cell transplantation with CD19 expression; 3. The estimated survival is over three months; 4. ECOG performance status of <=2 at study entry; 5. The important organs are function,such as heart and brain; 6. Understand and voluntarily sign an informed consent form.
Exclusion criteria
Exclusion criteria: 1. The uncontroled infection. HBV and HCV are positive; 2. The patients received any cell immunotherapy in the past.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| One-year disease-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| The rate of overall survival;The rate of infection; | — |
Countries
China
Contacts
Public ContactZhang Cheng
Department of Hematology, Xinqiao Hospital, Third Military Medical University, Chongqing, 400037, People's Republic of China.
Outcome results
None listed